. Author manuscript; available in PMC: 2022 Oct 14.

Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1482–1486. doi: 10.1158/1078-0432.CCR-21-3074

Table 2.

Overall Response Rates (ORR) Amongst Patients with KRAS G12C-Mutated NSCLC Treated with Sotorasib in Dose Escalation Cohorts in Study CodeBreaK 100

Daily Dose (mg)	N	ORR N (%) (95% CI)
180	3	1 (33) (0.8, 91)
360	16	4 (25) (7, 52)
720	6	3 (50) (12, 88)
960	34	16 (47) (30, 65)

CI, confidence interval; ORR, overall response rate.

Source: U.S. Food and Drug Administration. NDA Multi-disciplinary Review and Evaluation (NDA 214665) and Approval Package: LUMAKRAS (sotorasib) (ref 19).